TET2 and acute promyelocytic leukemia: We then assessed the activity of EAPB02303 on primary leukemic blasts derived from AML patients (patient 1 and 6 harbored NPM1 mutation, patient 2 had acute promyelocytic leukemia (APL), patient 3 harbored inversion INV(16), patient 4 expressed DNMT3A/IDH2/TET2/EZH2 mutations, and P5 expressed wt-NPM1/IKZF1/PTPN1/RUNX1) (AML patients’ information is detailed in Table 1).